## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-ibd/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-ibd/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-ibd/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-ibd/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-ibd/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-ibd` v2 · content_hash `642032fb3a58fb77…` · thread_head genesis · 23 DIVs
- **thesis (c1):** Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.
  - c2 [human/active] Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.
  - c3 [human/active] Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.
  - c4 [human/active] One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.
  - c5 [preclinical/active] Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.
  - c6 [anecdotal/active] Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-ibd/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-ibd/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-ibd`
- **title:** Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits
- **url:** https://miscsubjects.com/a/retatrutide-ibd
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:17.830Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have IBD (Crohn's / colitis)

IBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.

## Why Retatrutide might help you

1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.
2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.
3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.
4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

If your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Retatrutide** → metabolic load / body weight

Retatrutide focuses solely on the metabolic load layer in this framing. Other potential layers in IBD, such as direct mucosal repair or inflammation control, would require separate compounds if stacked later. The approach avoids overlap by isolating weight-related mechanical factors from gut-specific degeneration.

## What the evidence actually shows

Human trials for retatrutide show substantial weight loss but no dedicated IBD endpoints. A phase 2 study in adults with obesity reported up to 24.2% body weight reduction at 48 weeks with the 12 mg dose versus 2.1% on placebo (human tier). Phase 3 topline data indicated up to 30% loss at longer follow-up in severe obesity cohorts (human tier). These confirm metabolic effects but do not test Crohn's or colitis activity.

GLP-1 class observational data in IBD patients (mostly semaglutide or liraglutide) show weight loss of roughly 9-12 kg at 3 months and, in some cohorts, lower rates of surgery or hospitalization, especially in obese subgroups (human tier, observational). One cohort found no change in IBD activity despite >6% weight loss, with common nausea (human tier). Preclinical animal models of colitis suggest GLP-1 signaling may reduce inflammation markers, but retatrutide-specific rat or mouse IBD studies are absent (preclinical tier for class only).

Reddit threads discuss users with Crohn's inquiring about retatrutide compatibility or side effects, with no controlled reports (anecdotal tier). X posts mirror this pattern of personal queries without outcome data (anecdotal tier).

## What scientists say

Reviews note GLP-1 agonists achieve weight loss in IBD populations with a safety profile similar to non-IBD groups, while calling for prospective RCTs to test anti-inflammatory or disease-modifying effects (mechanistic/speculative tier beyond weight). No statements endorse retatrutide specifically for IBD remission or repair.

## What people say on Reddit

Users in retatrutide communities ask about Crohn's interactions or complications, citing personal research but no shared trial-level outcomes. Posts remain exploratory rather than testimonial of benefit or harm (anecdotal tier).

## What people say on X

Similar anecdotal queries appear around retatrutide use alongside IBD diagnoses, focused on tolerability rather than measured improvements in gut symptoms (anecdotal tier).

## What we do not know

No human trials exist for retatrutide in active IBD. Direct effects on mucosal healing, flare frequency, or steroid needs remain untested. Long-term IBD-specific safety data are absent. Weight-loss benefits do not automatically translate to gut repair.

## Safety and limits

Retatrutide human trials report gastrointestinal side effects as most common, dose-related, and often mild to moderate. Heart rate increases occurred in a dose-dependent pattern that later declined. In IBD observational work on the class, nausea and diarrhea appeared frequently, sometimes leading to discontinuation. Evidence does not establish retatrutide as a repair agent for IBD inflammation; any role stays limited to metabolic load considerations in comorbid obesity. All claims require professional medical context; this is evidence inventory only.

## Claims (6)

- **c1** [human w=0.8] Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [human w=0.8] One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.
  - who_claims: grok/grok-4.3
  - sources: s4
- **c5** [preclinical w=0.5] Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c6** [anecdotal w=0.3] Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.
  - who_claims: grok/grok-4.3
  - sources: s6

## Voxel graph (6 atoms · 12 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-ibd/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (6)
- chain valid: yes · head: `fa4eec819108b622`

### s1 · pubmed · http_403
- title: Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- url: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- summary: Phase 2 trial results showing dose-dependent weight loss with retatrutide.
- quote: At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide... the 12-mg group... −24.2%
- claim_ids: c1
- hash: `a278d79912605fda`

### s2 · news · ok
- title: Phase III retatrutide study demonstrates 30% weight loss
- url: https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss
- summary: Topline phase 3 weight loss outcomes for retatrutide.
- quote: participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss... at 104 weeks
- claim_ids: c2
- hash: `969ea15592ef8437`

### s3 · pubmed · http_403
- title: Glucagon-like peptide 1 receptor agonists and the clinical course of IBD
- url: https://academic.oup.com/ecco-jcc/article/19/10/jjaf181/8280408
- summary: Meta-analysis of GLP-1 RAs in IBD showing weight and outcome associations.
- quote: Weight loss was achieved using semaglutide (−9.6 kg... tirzepatide (−11.8 kg... GLP1-RAs were associated with lower risk of surgery... and reduced risk of hospitalization in the subset of obese patients
- claim_ids: c3
- hash: `5dfe4d4b3d50561d`

### s4 · medical · ok
- title: The Potential for GLP-1s in the Treatment of Crohn's Disease
- url: https://resources.healthgrades.com/pro/the-potential-for-glp-1s-in-the-treatment-of-crohns-disease
- summary: Cohort study noting weight loss without IBD activity change and GI side effects.
- quote: these patients successfully lost more than 6% of their body weight, but the treatment had no effect on IBD activity... nausea was very common and one patient withdrew due to diarrhea
- claim_ids: c4
- hash: `fcc1f8e2d5592f81`

### s5 · review · http_403
- title: GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease
- url: https://www.mdpi.com/2227-9059/13/5/1128
- summary: Systematic review contrasting preclinical colitis signals with clinical evidence gaps.
- quote: there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis... lack of prospective clinical studies
- claim_ids: c5
- hash: `1849c741dafdfb9c`

### s6 · reddit · ok
- title: reta with crohns
- url: https://www.reddit.com/r/Retatrutide/comments/1q37uvg/reta_with_crohns/
- summary: User inquiry on retatrutide compatibility with Crohn's, no outcome data.
- quote: i was wondering if anyone knew about any complications for if i take reta while having crohn's disease or any other IBD
- claim_ids: c6
- hash: `fa4eec819108b622`

## Provenance (2 model passes)
- chain valid: yes · head: `8e4c8ad31d0a6715`

- write · grok/grok-4.3 · 2026-06-30T00:58 · hash `d5e9aa078191`
- voxel_divide · owner · 2026-07-17T02:41 · hash `8e4c8ad31d0a`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-ibd/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-ibd/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-ibd","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-ibd|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-ibd|tier|assertion`
- **iMessage ask:** `retatrutide-ibd|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-ibd/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*